| Name | Ixico |
|---|---|
| Epic | IXI |
| Isin | GB00BFXR4C20 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 12.75p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £11.82 | Debt ratio | n/a |
| Shares in issue | 48.35 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -25.33 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -2.44 | 52-week high / low | 6.45p / 15.25p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Ixico |
|---|---|
| Address | 4th Floor, Griffin Court, 15 Long Lane, London. United Kingdom., EC1A 9PN |
| Telephone | +44 (0)20 3763 7499 |
| Website | http://ixico.com/ |
| Director | Position |
|---|---|
| Mr Giulio Cerroni | CEO |
| Ms Kate Rogers | Non-Executive Director |
| Mr Charles Spicer | Non-Executive Chairman |
| Mr Mark Warne | Senior Independent Director |
| Mr Grant Nash | Chief Finance Officer |
| Ms Dipti Amin | Independent Non-Executive Director |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 30/09/23 | 30/09/22 | 30/09/21 |
| Intangible asssets and goodwill | 6.15 | 4.59 | 2.71 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 6.7 | 5.4 | 3.79 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 1.71 | 3.03 | 3.31 |
| Cash and equivalents | 4.03 | 5.77 | 6.68 |
| Other current assets and asset held for resale | 0.55 | 0.45 | 0.48 |
| Total of all assets | 12.99 | 14.65 | 14.26 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 1.28 | 1.74 | 2.15 |
| Long term liabilities | 0.28 | 0.43 | 0.63 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 1.56 | 2.16 | 2.78 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 11.43 | 12.49 | 11.48 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 0.48 | 0.48 | 0.48 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -7.36 | -6.23 | -7.34 |
| Share premium account | 84.8 | 84.8 | 84.8 |
| Total equity | 11.43 | 12.49 | 11.48 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -1.44 | 0.91 | 1.12 |
| Pre-tax profit | -1.36 | 0.89 | 1.1 |